Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ABBV - Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

ABBV - Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

AbbVie Inc.

2024-01-28 02:56:00 ET

Summary

  • Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunctivitis.
  • The company has an option agreement with AbbVie, indicating strategic M&A value and potential for a takeover.
  • ALDX's current market cap of $181.76 million is mostly its cash value of $144.33 million, making it a strong buy with significant upside potential.
  • I conclude the company has an asymmetric risk-reward profile due to its low valuation (mostly in cash) vis a vis substantial potential payments from ABBV's option agreement deal.

...

For further details see:

Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
Stock Information
Company Name: AbbVie Inc.
Stock Symbol: ABBV
Market: NYSE
Website: abbvieinvestor.com
Menu
ABBV ABBV Quote ABBV Short ABBV News ABBV Articles ABBV Message Board
Get ABBV Alerts

News, Short Squeeze, Breakout and More Instantly...